Navigation Links
New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
Date:3/10/2008

PALO ALTO, Calif., March 10 /PRNewswire-FirstCall/ -- Varian, Inc. (Nasdaq: VARI) announced today its new XSens(TM) Dual Cold Probe. Designed for use with the Varian NMR System, the new probe is Varian's most sensitive probe for 13C detected NMR experiments.

The XSens Probe offers productivity and data quality enhancements for researchers in pharmaceutical, agricultural, chemical and academic laboratories involved in the characterization of quantity-limited samples of natural products, reaction intermediates, metabolites and trace contaminants.

The new probe dramatically increases 13C sensitivity and reduces acquisition time 100-fold compared to a room temperature (RT) Dual Broadband (DB) probe. It also offers a significantly improved 1H sensitivity, reducing acquisition time for 1H detected experiments 75-fold compared to a RT DB probe. In addition to increasing throughput, the enhanced sensitivity for 13C makes it easier for researchers to take advantage of the simpler spectral information available from 13C experiments.

"The XSens Probe is a significant advance in Cold Probe technology," said Martin O'Donoghue, Senior Vice President, Scientific Instruments, Varian, Inc. "By greatly reducing acquisition times, this probe makes previously time- consuming 13C detected NMR analyses a more practical tool for busy laboratories."

For more technical information about Varian's NMR instrumentation, please visit http://www.varianinc.com/products/

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 3,900 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is traded on the NASDAQ Global Select Market under the symbol, "VARI." Further information is available on the company's Web site: http://www.varianinc.com.


'/>"/>
SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
2. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
3. Carl Hull Named President and Chief Operating Officer of Gen-Probe
4. Cascade Microtech Introduces Worlds First 45 nm-capable DC/RF Parametric Probe Card Solutions, Lowers Cost of Ownership
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
7. Gen-Probe to Webcast Three Upcoming Presentations
8. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
9. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
10. New FTMS System From Varian, Inc. Offers Switchable LC and GC Sources and True Triple Quadrupole Capabilities
11. New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):